Abstract
We evaluated the estrogen receptor (ER) phenotype of recurrent and/or metastatic breast cancers and compared it with the ER status of the primary tumor in 278 cases. All patients had undergone surgical excision of the primary tumor, followed by observation only or treatment modalities that included radiation and/or chemotherapy or hormonal therapy. The immunohistochemical expression of ER was evaluated by using monoclonal antibody ER-1D5 and heat-induced antigen retrieval. At diagnosis, 165 patients had locoregional disease and 7 had distant metastases. Local recurrences and/or distant metastases occurred from 2 months to 21 years after the diagnosis of the primary tumor. Overall, 159 primary tumors (57.2%) were positive for ER. In 269 cases (96.8%), the ER status of the primary and metastatic tumors was the same. In 9 patients with ER+ primary tumors, the metastases were ER-. There were no ER- primary tumors with ER+ metastases. The time to distant metastasis was significantly longer for ER+ tumors. The immunohistochemically determined ER phenotype of primary breast cancers remains stable in most recurrent and metastatic disease.
| Original language | English |
|---|---|
| Pages (from-to) | 879-882 |
| Number of pages | 4 |
| Journal | American Journal of Clinical Pathology |
| Volume | 130 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 1 2008 |
Fingerprint
Keywords
- Breast cancer
- Estrogen receptor
- Immunohistochemistry
- Metastatic breast carcinoma
ASJC Scopus subject areas
- Pathology and Forensic Medicine
Cite this
Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. / Gomez-Fernandez, Carmen; Daneshbod, Yahya; Nassiri, Mehdi; Milikowski, Clara; Alvarez, Consuelo; Nadji, Mehrdad.
In: American Journal of Clinical Pathology, Vol. 130, No. 6, 01.12.2008, p. 879-882.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer
AU - Gomez-Fernandez, Carmen
AU - Daneshbod, Yahya
AU - Nassiri, Mehdi
AU - Milikowski, Clara
AU - Alvarez, Consuelo
AU - Nadji, Mehrdad
PY - 2008/12/1
Y1 - 2008/12/1
N2 - We evaluated the estrogen receptor (ER) phenotype of recurrent and/or metastatic breast cancers and compared it with the ER status of the primary tumor in 278 cases. All patients had undergone surgical excision of the primary tumor, followed by observation only or treatment modalities that included radiation and/or chemotherapy or hormonal therapy. The immunohistochemical expression of ER was evaluated by using monoclonal antibody ER-1D5 and heat-induced antigen retrieval. At diagnosis, 165 patients had locoregional disease and 7 had distant metastases. Local recurrences and/or distant metastases occurred from 2 months to 21 years after the diagnosis of the primary tumor. Overall, 159 primary tumors (57.2%) were positive for ER. In 269 cases (96.8%), the ER status of the primary and metastatic tumors was the same. In 9 patients with ER+ primary tumors, the metastases were ER-. There were no ER- primary tumors with ER+ metastases. The time to distant metastasis was significantly longer for ER+ tumors. The immunohistochemically determined ER phenotype of primary breast cancers remains stable in most recurrent and metastatic disease.
AB - We evaluated the estrogen receptor (ER) phenotype of recurrent and/or metastatic breast cancers and compared it with the ER status of the primary tumor in 278 cases. All patients had undergone surgical excision of the primary tumor, followed by observation only or treatment modalities that included radiation and/or chemotherapy or hormonal therapy. The immunohistochemical expression of ER was evaluated by using monoclonal antibody ER-1D5 and heat-induced antigen retrieval. At diagnosis, 165 patients had locoregional disease and 7 had distant metastases. Local recurrences and/or distant metastases occurred from 2 months to 21 years after the diagnosis of the primary tumor. Overall, 159 primary tumors (57.2%) were positive for ER. In 269 cases (96.8%), the ER status of the primary and metastatic tumors was the same. In 9 patients with ER+ primary tumors, the metastases were ER-. There were no ER- primary tumors with ER+ metastases. The time to distant metastasis was significantly longer for ER+ tumors. The immunohistochemically determined ER phenotype of primary breast cancers remains stable in most recurrent and metastatic disease.
KW - Breast cancer
KW - Estrogen receptor
KW - Immunohistochemistry
KW - Metastatic breast carcinoma
UR - http://www.scopus.com/inward/record.url?scp=58049217550&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58049217550&partnerID=8YFLogxK
U2 - 10.1309/AJCPD1AO3YSYQYNW
DO - 10.1309/AJCPD1AO3YSYQYNW
M3 - Article
VL - 130
SP - 879
EP - 882
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
SN - 0002-9173
IS - 6
ER -